No Data
No Data
Ch Biotech Ser (08037.HK) plans to issue 12.5 million shares in a reverse inquiry, raising a total of HKD 5 million.
On July 21st, Gelonhui reported that China Biotech Services (08037.HK) announced that on July 20, 2024, Genius Lead entered into a placement agreement, whereby Genius Lead agreed to sell 12.5 million shares to the placing agent (i.e. Mr. Ming Fu) at a price of HKD 0.40 per share. On the same day, Genius Lead entered into a pre-old-and-new subscription agreement with the Company. According to the pre-old-and-new subscription agreement, the Company conditionally agreed to issue and distribute shares, while Genius Lead conditionally agreed to subscribe for 12.5 million shares.
China Biotech Services Holdings Limited's (HKG:8037) 28% Share Price Surge Not Quite Adding Up
CH Biotech Ser (08037): Xu Haiyin resigns as non-executive director.
Ch Biotech Ser (08037) announced that Ms. Xu Haiyin has resigned as a non-executive director of the company, effective from 202...
Ch Biotech Ser (08037): Guo Yuantao has been appointed as an independent non-executive director.
Ch Biotech Ser (08037) announced that Guo Yuantao has been appointed as an independent non-executive director, as well as a member of the audit committee, nomination committee, and remuneration committee, effective immediately following the annual general meeting of shareholders.
ch biotech ser announced clinical trial results at the American ASCO 2024 annual meeting.
CH Biotech Ser (08037) announced that its indirectly non-wholly-owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., presented the results of Phase I clinical study on LY007 cell injection (a new autologous chimeric antigen receptor T-cell therapeutic product targeting CD20) for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in the form of a poster exhibition. It is reported that diffuse large B-cell lymphoma (DLBCL) (LBC
ch biotech ser (08037) announced the clinical trial results at the 2024 annual meeting of the American Society of Clinical Oncology.
Zhìtōng Cáijīng APP reports that CH Biotech Ser (08037) released an announcement that its indirectly non-wholly owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., showcased the results of its Phase I clinical trial of LY007 cell injection (a new autologous chimeric antigen receptor T cell therapy product targeting CD20) in patients with relapsed/refractory B cell non-Hodgkin's lymphoma (B-NHL) at the American Society of Clinical Oncology (ASCO) 2024 annual meeting in the form of a poster presentation. It is reported that diffuse large B-cell lymphoma (DLBCL) is one of the most aggressive, heterogeneous, and common subtypes of B-cell NHL, accounting for approximately 40% of cases in China.
No Data